EBV Related PTCL clinical trials at UCSF

1 in progress, 0 open to eligible people

Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
Sorry, in progress, not accepting new patients
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas
San Francisco, California and other locations

Last updated: January 6, 2025